CONJUGATED ESTROGENS
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Conjugated estrogens bind to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting estrogenic effects on target tissues, including the endometrium, breast, and bone. They increase hepatic synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin, and other proteins, and have effects on lipid metabolism, coagulation factors, and vasodilation via nitric oxide.
| Metabolism | Primarily hepatic metabolism via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C9, CYP2C19) and conjugation (glucuronidation, sulfation). Enterohepatic recirculation occurs. Metabolites are excreted in urine and bile. |
| Excretion | Renal: 40–50% as glucuronide conjugates; biliary/fecal: ~20% as free and conjugated forms. |
| Half-life | 10–24 hours (terminal); clinical context: requires daily dosing for stable hormone levels. |
| Protein binding | 98–99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | 1.4–2.2 L/kg; indicates extensive distribution into tissues, including breast and reproductive organs. |
| Bioavailability | Oral: 30–50% due to extensive first-pass metabolism; transdermal: ~100%. |
| Onset of Action | Oral: 2–4 weeks for vasomotor symptom relief; transdermal: 2–4 weeks. |
| Duration of Action | 24 hours; clinical notes: daily administration required for continuous effect. |
0.625 mg orally once daily for menopausal symptoms; 1.25 mg orally three times daily for 2-3 weeks for abnormal uterine bleeding; 25 mg intravenously or intramuscularly every 6-12 hours for postpartum hemorrhage.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment is recommended based on GFR; use with caution in severe renal impairment due to potential fluid retention. |
| Liver impairment | Contraindicated in Child-Pugh class C (severe hepatic impairment). Dose adjustment not defined for Child-Pugh A or B; avoid use if active liver disease. |
| Pediatric use | Not approved for use in children; no established weight-based dosing. Use only in specific conditions like Turner syndrome under specialist guidance. |
| Geriatric use | Use lowest effective dose for shortest duration due to increased risks of DVT, stroke, and dementia. No specific dose adjustment, but monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
| Breastfeeding | Conjugated estrogens are excreted in human milk in small amounts (M/P ratio not established). Use during lactation may reduce milk production and composition. Breastfeeding is generally not recommended due to potential adverse effects on the infant (e.g., estrogenic effects). |
| Teratogenic Risk | Conjugated estrogens are contraindicated in pregnancy. First trimester: increased risk of fetal genital tract abnormalities (e.g., vaginal adenosis, cervical ectropion) and potential transplacental carcinogenesis (clear cell adenocarcinoma in female offspring). Second and third trimesters: no established safe use; may cause fetal harm. U.S. FDA Pregnancy Category X. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women. Do not use estrogen-alone therapy in women with a uterus without concomitant progestin. Estrogen plus progestin therapy increases the risk of stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction in postmenopausal women. Estrogen plus progestin therapy increases the risk of invasive breast cancer. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis. Do not use estrogens for the prevention of cardiovascular disease or dementia.
| Common Effects | osteoporosis prevention |
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active or history of venous thromboembolism (DVT, PE)","Active or history of arterial thromboembolism (stroke, MI)","Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency)","Hypersensitivity to estrogens or any excipient","Hepatic impairment or disease","Pregnancy"]
| Precautions |
Loading safety data…
| Fetal Monitoring | Not applicable in pregnancy (contraindicated). For inadvertent exposure: monitor fetal growth, amniotic fluid index, and consider fetal echocardiography for potential cardiovascular effects. No routine monitoring recommended for lactation. |
| Fertility Effects | Conjugated estrogens may impair fertility by suppressing gonadotropin secretion, inhibiting ovulation, and altering endometrial receptivity. Use for contraception or hormone therapy can temporarily reduce fecundity. Effects are reversible upon discontinuation. |
| ["Cardiovascular disorders: increased risk of stroke, DVT, PE, MI","Malignant neoplasms: endometrial cancer, breast cancer (especially with progestin)","Dementia: possible increased risk in women ≥65 years","Gallbladder disease","Hypertriglyceridemia","Fluid retention","Hypocalcemia in hypoparathyroidism","Retinal vascular thrombosis","Hereditary angioedema exacerbation","Impaired liver function or history of cholestatic jaundice","Exacerbation of endometriosis","Uterine leiomyomata","Porphyria exacerbation"] |